MS-325: Albumin-targeted contrast agent for MR angiography
MS-325: Albumin-targeted contrast agent for MR angiography
复制标题
DOI：
10.1148/radiology.207.2.9577506
复制
发表时间：
1998-05-01
期刊：
影响因子：
19.7
通讯作者：
Walovitch, RC
中科院分区：
文献类型：
--
作者：
Lauffer, RB;Parmelee, DJ;Walovitch, RC
目的：评估MS - 325（一种基于钆的磁共振成像血池造影剂，可与白蛋白结合）的蛋白质结合及信号增强特性，并将结果与现有的基于钆和氧化铁的造影剂所获结果进行比较。
材料与方法：通过超滤法测量人血浆中的蛋白质结合情况。在注射了每千克体重0.1毫摩尔MS - 325的兔和猴的人血浆或离体样本中测量T1弛豫时间（20兆赫兹）。在体模（包含不同浓度的不同造影剂）中或在注射了0.015 - 0.100毫摩尔/千克MS - 325的兔体内，于1.0特斯拉下进行成像（稳态进动三维快速成像，即FISP）。
结果：MS - 325在人血浆中的结合率为80% - 96%，其弛豫率约为钆喷酸二乙三胺五乙酸（DTPA）的6到10倍。含有MS - 325的体模图像在相同浓度下明显比含有现有钆螯合物或铁颗粒（单晶氧化铁纳米颗粒，即MION）的图像更亮。体内研究结果表明，MS - 325可使血浆T1在1小时内显著且持续降低（MS - 325的T1为50 - 100毫秒，Gd - DTPA的T1为200 - 400毫秒），并且在磁共振图像上血管增强明显。
结论：MS - 325注射后与蛋白质高度结合，其提供的血管信号增强效果优于其他造影剂。作为首个进入人体试验的基于钆的血池造影剂，MS - 325有可能增强动态和稳态磁共振血管造影图像。
PURPOSE: To evaluate the protein-binding and signal enhancement characteristics of MS-325, a gadolinium-based magnetic resonance (MR) imaging blood pool agent that binds to albumin, and compare results with those obtained with existing gadolinium- and iron oxide-based agents.MATERIALS AND METHODS: Protein binding in human plasma was measured by means of ultrafiltration. T1 relaxation times (20 MHz) were measured in human plasma or ex vivo samples from rabbits and monkeys injected with 0.1 mmol of MS-325 per kilogram of body weight. Imaging (three-dimensional fast imaging with steady-state precession, or FISP) was performed at 1.0 T in phantoms, which contained varying concentrations of different agents, or rabbits after injection of 0.015-0.100 mmol/kg MS-325.RESULTS: MS-325 is 80%-96% bound in human plasma and exhibits a relaxivity approximately six to 10 times that of gadolinium diethylenetriaminepentaacetic acid (DTPA). Images of phantoms containing MS-325 were significantly brighter than those containing existing gadolinium chelates or iron particles (monocrystalline iron oxide nanoparticle, or MION) at equivalent concentrations. Findings of in vivo studies indicated strong, persistent plasma T1 reduction with MS-325 for 1 hour (T1 of MS-325, 50-100 msec, T1 of Gd-DTPA, 200-400 msec) and strong vascular enhancement on MR images.CONCLUSION: MS-325 is highly protein bound after injection and provides vascular signal enhancement superior to that provided with other agents. As the first gadolinium-based blood pool agent in human trials, MS-325 has the potential to enhance both dynamic and steady-state MR angiograms.